2010 NICE人类生长激素治疗儿童生长障碍
Human growth hormone (somatropin) for the treatment of growth failure in children
2010-05-01
NOTE: This guidance replaces ‘NICE technology appraisal guidance 42’ issued in May 2002.The review and re-appraisal of human growth hormone (somatropin) for the treatment of growth failure inchildren has resulted in a change in the guidance. Human growth hormone (somatropin) is still recommended forthe treatment of growth failure in children with growth hormone deficiency, Turner syndrome, Prader–Willisyndrome and chronic renal insufficiency, but there has been an extension of the guidance to include growthfailure associated with either of the two following conditions:• born small for gestational age with subsequent growth failure at 4 years of age or later• short stature homeobox-containing gene (SHOX) deficiency.